Novartis AG (NVS) Shares are Down -1.25%

Novartis AG (NVS) has risen sharply, recording gains of 0.58% in the past 4 weeks. However, the stock has corrected -1.25% in the past 1 week, providing a good buying opportunity on dips. Novartis AG (NVS) : During the past 4 weeks, traders have been relatively bearish on Novartis AG (NVS), hence the stock is down -0.45% when compared to the S&P 500 during the same period. However, in the past 1 week, the selling of the stock is down by -1.3% relative to the S&P 500.

The stock has recorded a 20-day Moving Average of 0.73% and the 50-Day Moving Average is 1.11%. Novartis AG (NYSE:NVS): On Fridays trading session , Opening price of the stock was $82.27 with an intraday high of $82.4. The bears continued to sell at higher levels and eventually sold the stock down to an intraday low of $81.9. However, the stock managed to close at $82.08, a loss of 0.87% for the day. On the previous day, the stock had closed at $82.8. The total traded volume of the day was 1,366,989 shares.


The company Insiders own 0.01% of Novartis AG shares according to the proxy statements. Institutional Investors own 10.05% of Novartis AG shares.

Novartis AG is a holding company that, through its subsidiaries, is engaged in development, manufacturing and marketing of a range of healthcare products led by pharmaceuticals around the world. Its portfolio includes medicines, eye care, generic pharmaceuticals, preventive vaccines and over-the-counter (OTC) products. The Companys segments include Pharmaceuticals, which include patent-protected prescription medicines; Alcon, which include surgical, ophthalmic pharmaceutical and vision care products; Sandoz, which include generic pharmaceuticals, and Consumer Health, which includes the OTC Division. Pharmaceuticals products include Afinitor/Votubia, Exjade, Galvus, Exforge and Voltaren, among others. Its Sandoz products include Valsartan (Diovan), Cyclophosphamide injection and AirFluSal Forspiro, among others. Its OTC offers readily available consumer medicine. The Company operates Admune Therapeutics as a wholly owned subsidiary.

Comments (0)

Leave a Reply

Your email address will not be published. Required fields are marked *